This study first investigated clinical and prognostic features of advanced adenocarcinoma according to EGFR mutation status in Korean patients, particularly for specific EGFR mutation types (mutations in E18, E19, E20, and E21). This evidence concerns the gene EGFR and adenocarcinoma.